* The Cyrcadia iTBra is not for public sale in the United States at this time.
Breast wellness
through early detection

The iTbra

iTBra consists of two comfortable and intelligent patches, worn underneath your garments, which detect circadian temperature changes in breast tissue. Anonymised data is communicated directly to the Cyrcadia’s core lab for analysis via your mobile device. Results are sent back to you within minutes.

The iTBra empowers women to monitor their own breast health, and detects breast cancer at its earliest possible stages.

Accessible

Easy to use, even in your own home and going about your daily rountine, an early breast health monitoring system.

Comfortable

No pressing. No pain. No radiation. No uncomfortable examinations.

Convenient

Discrete monthly wear anywhere, anytime.

How it works
1
Apply
The iTBra is designed to fit comfortably under your own garments or sportswear.
2
Power up
Make sure your Bluetooth® connection is enabled on your mobile device.

Download and launch the iTBra app and press start. The countdown timer will begin.
3
Do your thing
Wear the iTBra for a minimum of 2 hours. We’ll let you know when the process is complete.
4
You’re done
The results will be sent automatically to you and/or your physician within minutes.

Remove the patches and store for next month’s wear time.

Our Technology

Our technology is based on analysis of the human body’s natural 24-hour circadian cycles. These circadian cycles are driven by certain genes in our cells that regulate our metabolism. Those circadian cycles contain specific heat signatures and can be tracked metabolically.

It is well known that the formation of certain cancers, including in the breasts, are associated with disruption of circadian cellular genetic activity. While the circadian metabolic fluctuation in healthy tissue shows a wide profile, with tissue-invasive cancer, the disruption in the tissue’s metabolic processes causes the entire breast profile to flatten.

Our technology monitors changes in the metabolic profile over time. Thanks to the predictive power of our Artificial Intelligent foundation, within just a two hour segment our algorithms can distinguish between healthy and potentially cancerous metabolic profiles, no matter what your activity day or night. Our high rate of accuracy has been confirmed against actual patient pathology, not simply imaging interpretation.

The use of metabolic detection represents a breakthrough in cancer screening over image-based modalities such as mammography or ultrasound.

Much like a “snowflake in a snow storm”, interpretation of images in dense tissue can lead to cancers being missed, and to many unnecessary biopsies being conducted on non-cancerous tissue.

Many women are unaware that they have dense breasts and that their annual mammogram may miss the presence of cancer. Our technology does not rely on imaging, therefore we achieve the same levels of accuracy in detection regardless of breast tissue density, bring peace of mind to those women with dense tissue.

Our investigators believe the metabolic change we detect happens at the earliest stage of tumour formation in the tissue meaning that we can potentially find cancers when they are much smaller and more easily treatable. We can also distinguish, and rule out, other breast abnormalities that may appear as a suspicious lump on an image, but which are not invasive cancer.

Cancer detection by AI, not the naked eye.

Contact us for more information about our technology, or for information on dense breast tissue.

We find cancer earlier
Early detection means less biopsies & more lives saved

Find out more

Empowering woman with early detection

Our Team

Rob Royea
Rob Royea CEO & Co-Founder

Listed as one of the Top 40 Medical Transformers for 2016 by Medical Marketing and Management Magazine. Led global efforts of both public and private venture technologies, with demonstrated successes from start-up to over $550M. Positioned Cyrcadia to earn the prestigious Edison award in 2016 as the #1 company in Health and Wellness, Wearable and Sensors Category.

Dr. Shyamali Singhal
Dr. Shyamali Singhal Chief Medical Officer

M.D. & Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine. Specializes in surgical oncology for the treatment breast, melanoma, colon, stomach, liver and pancreatic cancer.

Dr, Vinitha Subbhuraam
Dr, Vinitha Subbhuraam Director - Analytic Core Lab

Ph.D. in Biomedical Engineering at Nanyang Technological University of Singapore. Brings 10+ years of experience in the medical analytics field, in applied predictive algorithms for the detection of cancers in the breast, ovaries, prostate and thyroid.

Tang Ying
Tang Ying Director - Business Development

Strong background in media and healthcare transactions in China including the formation of Yuxin Media and Cyrcadia Asia.

Rob Royea
Rob Royea CEO & Co-Founder

Listed as one of the Top 40 Medical Transformers for 2016 by Medical Marketing and Management Magazine. Led global efforts of both public and private venture technologies, with demonstrated successes from start-up to over $550M. Positioned Cyrcadia to earn the prestigious Edison award in 2016 as the #1 company in Health and Wellness, Wearable and Sensors Category.

Dr. Shyamali Singhal
Dr. Shyamali Singhal Chief Medical Officer

M.D. & Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine. Specializes in surgical oncology for the treatment breast, melanoma, colon, stomach, liver and pancreatic cancer.

Dr. Vinitha Subbhuraam
Dr. Vinitha Subbhuraam Director - Analytic Core Lab

Ph.D. in Biomedical Engineering at Nanyang Technological University of Singapore. Brings 10+ years of experience in the medical analytics field, in applied predictive algorithms for the detection of cancers in the breast, ovaries, prostate and thyroid.

Tang Ying
Tang Ying Director - Business Development

Strong background in media and healthcare transactions in China including the formation of Yuxin Media and Cyrcadia Asia.

Dr. Claudia S. Dyckerhoff
Dr. Claudia S. Dyckerhoff Director

PhD in business administration and an MBA. Formerly a senior partner at McKinsey with over 10 years of experience in the Asian healthcare and health insurance sectors, leading McKinsey’s China Healthcare Sector team and its Asian Health Services and Systems team until stepping down in 2016. Is currently a Director of Roche AG and Clariant AG.

Mark Chennells
Mark Chennells Co-Founder & Director

Specialised in corporate mergers, acquisitions and restructurings in NZ, Australia, USA, UK and China. Brings over 20 years experience advising and investing in China, during which time he has helped to found several companies and has advised a number of Chinese companies on their international acquisitions.

Chris Bailey
Chris Bailey Co-Founder & Director

Chris’ professional experience includes acting as an Executive with the IP specialist firm, Rouse (www.rouse.com). Chris brings 18 years of experience in advising overseas companies on the management, protection and commercialisation of their IP assets in China and other countries in Asia.

Dr. Claudia S. Dyckerhoff
Dr. Claudia S. Dyckerhoff Director

PhD in business administration and an MBA. Formerly a senior partner at McKinsey with over 10 years of experience in the Asian healthcare and health insurance sectors, leading McKinsey’s China Healthcare Sector team and its Asian Health Services and Systems team until stepping down in 2016. Is currently a Director of Roche AG and Clariant AG.

Mark Chennells
Mark Chennells Co-Founder & Director

Specialised in corporate mergers, acquisitions and restructurings in NZ, Australia, USA, UK and China. Brings over 20 years experience advising and investing in China, during which time he has helped to found several companies and has advised a number of Chinese companies on their international acquisitions.

Chris Bailey
Chris Bailey Co-Founder & Director

Chris’ professional experience includes acting as an Executive with the IP specialist firm, Rouse (www.rouse.com). Chris brings 18 years of experience in advising overseas companies on the management, protection and commercialisation of their IP assets in China and other countries in Asia.

Awards & Publicity
‘Detected Documentary’ by Ironbound Films
Excerpts can be found on ‘Detected Movie’ YouTube channel
Purchase the full documentary here
Winner of two Cannes Lions awards